Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
D 15.18 -3.31% -0.52
BYSI closed up 1.75 percent on Monday, September 27, 2021, on 21 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical BYSI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction -3.31%
Wide Bands Range Expansion -3.31%
Up 3 Days in a Row Strength -3.31%
Oversold Stochastic Weakness -3.31%
Narrow Range Bar Range Contraction -1.62%
Wide Bands Range Expansion -1.62%
Oversold Stochastic Weakness -1.62%
Narrow Range Bar Range Contraction -1.11%
NR7 Range Contraction -1.11%
NR7-2 Range Contraction -1.11%
Older End-of-Day Signals for BYSI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 1 hour ago
Possible Inside Day about 1 hour ago
60 Minute Opening Range Breakdown about 3 hours ago
Down 5% about 3 hours ago
Down 3% about 5 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


BeyondSpring, Inc. Description

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatments Chemotherapy Small Cell Lung Cancer Antineoplastic Drugs Cancer Therapies Organic Chemistry Nsclc Protein Kinase Docetaxel Advanced Non Small Cell Lung Cancer Neutropenia Buparlisib Imidazoles

Is BYSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.0
52 Week Low 8.9
Average Volume 4,233,415
200-Day Moving Average 13.64
50-Day Moving Average 19.82
20-Day Moving Average 22.23
10-Day Moving Average 18.38
Average True Range 2.35
ADX 32.69
+DI 18.82
-DI 28.47
Chandelier Exit (Long, 3 ATRs) 25.95
Chandelier Exit (Short, 3 ATRs) 21.76
Upper Bollinger Bands 32.17
Lower Bollinger Band 12.29
Percent B (%b) 0.17
BandWidth 89.41
MACD Line -1.76
MACD Signal Line -0.52
MACD Histogram -1.2342
Fundamentals Value
Market Cap 614.52 Million
Num Shares 39.1 Million
EPS -1.90
Price-to-Earnings (P/E) Ratio -8.27
Price-to-Sales 0.00
Price-to-Book 18.22
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.41
Resistance 3 (R3) 17.30 16.62 17.13
Resistance 2 (R2) 16.62 16.18 16.68 17.03
Resistance 1 (R1) 16.16 15.92 16.39 16.27 16.93
Pivot Point 15.48 15.48 15.60 15.54 15.48
Support 1 (S1) 15.02 15.04 15.25 15.13 14.47
Support 2 (S2) 14.34 14.78 14.40 14.37
Support 3 (S3) 13.88 14.34 14.28
Support 4 (S4) 13.99